Instacart (NASDAQ:CART) traded nearly 4% lower, to $33.40, as the Nasdaq’s newest listing retreats back towards the IPO offer price – after yesterday’s initially giddy market debut temporarily spiked the market price by over 40%.
The grocery shopping and delivery app firm raised its IPO price to $30 a share on Monday valuing the company at about $10 billion, after previously setting a price range of $26 to $28 last week.
Arm Holdings PLC (NASDAQ:ARM) was similarly pitched lower in Wednesday’s early deals, as last week’s IPO darling also sees something of a comedown from its immediate float-hype. At $54.24 in today’s early deals the semiconductor firm was 1.7% lower than yesterday’s close.
Klaviyo is next up in the mini-IPO revival that’s caught the market’s attention, with the marketing automation company set to make its debut later today.
Like Instacart (NASDAQ:CART) and ARM, the imminent float saw some eleventh-hour bullishness with the IPO pricing above the previously set pricing range – its shares were sold at $30 apiece valuing the business at just over $9 billion, whilst earlier in the week the range was set at $27 to $29 earlier in the week.
Goldman Sachs (NYSE:GS), down 0.2% in premarket deals, its in “advanced talks” over the sale of home renovations loan business GreenSky, according to a Wall Street Journal report, as the banks efforts to exit non-core businesses evidently continues.
GreenSky may be sold for around $500 million, the report suggests, which would mark a significant loss from the $1.7 billion Goldman paid in its 2021 acquisition of the lender.
Steelcase Inc (NYSE:SCS) stock was up around 3%, at $9.08, in early deals after the office furniture firm gave more upbeat outlook amidst the trend for ‘back to office’ mandates across many business sectors in 2023.
As more employers revert, either to full-time or hybrid office work, the company said it was “optimistic” of improving demand for its chairs, desk and office storage products.
ARS Pharmaceutical (NASDAQ:SPRY) saw its stock plummet, losing 58% to $2.74, after the FDA failed to follow through on its own prior ‘advisory’ recommendation, as the company announced after yesterday’s market close that an application for Neffy, ARS’ epinephrine nasal spray, was rejected for treatment of severe allergic reaction.
The company now plans to resubmit an application next year.
Pinterest Inc (NYSE:PINS) stock was up 3.5%, at $27.13, after chief executive talked-up its growth prospects on an investor call on Tuesday afternoon.